Controlled air-inflation enclosed type myoma specimen smashing bag

Abstract

The invention provides a controlled air-inflation enclosed type myoma specimen smashing bag. The controlled air-inflation enclosed type myoma specimen smashing bag comprises an air-inflation bag, a sealing hole, a sealing strap, a strap casing, a laparoscope inlet, a left surgical operation hole, a right surgical operation hole and an air-inflation auxiliary feeding-in device, wherein the sealing hole is formed in an opening of the air-inflation bag; the sealing strap is connected to the sealing hole in a certain manner; the strap casing is arranged on the sealing strap in a sleeving manner; the left surgical operation hole and the right surgical operation hole are respectively formed in the left side and the right side of the bottom of the upper surface of the air-inflation bag; the laparoscope inlet is formed in the middle-lower part of the right edge of the upper surface of the air-inflation bag. According to the controlled air-inflation enclosed type myoma specimen smashing bag which adopts the design, a myoma smashing operation on a patient can be carried out safely and reliably; meanwhile, a smashed specimen in the operation can be collected, and abdominal cavity tissue pollution and malignant tissue dispersion are avoided. The controlled air-inflation enclosed type myoma specimen smashing bag also has the characteristics of simple structure, convenience in use, safety, reliability and the like and can be popularized and used in a large scale in clinical medicine.

Description

technical field [0001] The invention relates to a medical operation device, in particular to a controllable inflatable closed fibroid specimen crushing bag device. Background technique [0002] Minimally invasive surgery is becoming more and more popular in today's medical field. 80% of gynecological tumors can be completed by laparoscopic minimally invasive surgery. The accuracy rate of biopsy is only about 70%. At the same time, uterine fibroids and uterine sarcoma are currently operated without any protection. In this way, once uterine fibroids are crushed by mistake, they will be widely planted in the abdominal cavity, which will aggravate the The condition worsened. Therefore, in April this year, the U.S. Food and Drug Administration (FDA) issued a warning: when laparoscopic hysterectomy and uterine fibroids are removed, the use of fibroid morcellators may lead to the spread of hidden malignant tissues and reduce the possibility of survival. At present, there is no ef...

AI Technical Summary

Problems solved by technology

[0002] Minimally invasive surgery is becoming more and more popular in today's medical field. 80% of gynecological tumors can be completed by laparoscopic minimally invasive surgery. The accuracy rate of biopsy is only about 70%. At the same time, uterine fibroids and uterine sarcoma are currently operated without any protection. In this way, once uterine fibroids are crushed by mistake, they will be widely planted in the abdominal cavity, which will aggravate the worsening condition

Therefore, in April this year, the U.S. Food and Drug Administration (FDA) issued a warning: when laparoscopic hysterectomy and uterine fibroids are removed, the use of fibroid morcellators may lead to the spread of hidden malignant tissues and reduce the possibility of survival. At present, there is no effective method to identify uterine fibroids and sarcoma. Before there is no effective means to protect and prevent abdominal tissue contamination, it is not recommended to continue to use fibroid morcellators. Most doctors in the United States have stopped using fibroid morcellators. Nearly 200,000 uterine morcellators The surgical operation of patients has been challenged. This warning has restricted mature laparoscopic surgery. There are nearly one million patients with uterine morcellation in China every year. Whether to choose uterine morcellation and surgery will also face huge troubles.

Images